Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.40 |
| ▸ | ARHGDIA | P52565 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412677 | 0.82 | S1PR1 (0.42) | ROCK2ROCK1ARHGDIASLC6A2SLC6A4 | |
| SCHEMBL5422058 | 0.74 | RXRA (0.47) | — | |
| SCHEMBL5640590 | 0.73 | CHRM2 (0.61) | ROCK2ROCK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5404336 | 0.72 | ROCK2 (0.70) | ROCK2ROCK1ARHGDIACYP3A4 | |
| Hydrochloric Acid SCHEMBL5404775 | 0.72 | ROCK2 (0.69) | ROCK2ROCK1ARHGDIACYP3A4 | |
| SCHEMBL21761572 | 0.65 | SLC6A2 (0.47) | ROCK2ROCK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5413166 | 0.64 | ROCK2 (0.70) | ROCK2ROCK1ARHGDIACYP3A4 | |
| SCHEMBL5412656 | 0.63 | ROCK2 (0.73) | ROCK2ROCK1ARHGDIACYP3A4 | |
| SCHEMBL5815706 | 0.63 | SLC6A2 (0.49) | ROCK2ROCK1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL5412669 | 0.63 | ROCK2 (0.69) | ROCK2ROCK1ARHGDIACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885ARHGDIA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.